Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Timber Pharmaceuticals, Inc.BPMX · Entity 110330 | Pres and CEO | June 12, 2019 | June 14, 2019 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | March 09, 2023 | March 13, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Timber Pharmaceuticals, Inc.
Report date June 12, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2029-06-12 | Direct | 360,000 |
Reported balance
After 2019-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-12 · Grant · Acquired 360,000 · Balance 360,000 F1: This option vests and becomes exercisable ratably over 36 months |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable ratably over 36 months
ZEVRA THERAPEUTICS, INC.
Report date March 09, 2023 · Filed March 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,835 |
Reported balance
After 2023-03-09 transaction · row 1
1 source rowRow 1 · 2023-03-09 · Purchase · Acquired 5,000 · Balance 10,835 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CATALYST PHARMACEUTICALS, INC.
Report date July 15, 2026 · Filed July 17, 2026
Section 16 reporting ended · disclosed 2026-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Disposition to issuer · Disposed 383,314 · Balance 0 F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2026-12-02 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 33,500 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-12-30 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2028-12-28 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-15 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $18.59 · Expires 2029-12-27 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Disposition to issuer · Disposed 29,524 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.12 · Expires 2031-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Disposition to issuer · Disposed 23,248 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $22.77 · Expires 2032-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-15 · Disposition to issuer · Disposed 18,115 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-12-08 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-15 · Disposition to issuer · Disposed 1,414 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-07-15 · Disposition to issuer · Disposed 1,894 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-07-15 · Disposition to issuer · Disposed 5,468 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
F5: Each Option was fully vested.
F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2023 Filed Apr 7, 2023 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 30,000 | $16.83 | $504,900.00 |
DisclosureSEC source: 0001161697-23-000243 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,541 F1 · shares: Dr. Tierney has advised the Company that the sale of shares was to pay the exercise price of the shares and to raise funds for personal reasons, and does not relate to any disagreements between Dr. Tierney and the Company on any matter relating to the Company's operations, policies or practices. Dr. Tierney remains a Director of the Company. F2 · price: Shares were sold in various lots from $16.70 to $16.98 per share. The listed sales price represents a weighted average price for the shares sold. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 30,000 | $0.79 | $23,700.00 |
DisclosureSEC source: 0001161697-23-000243 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 11:54 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 5,000 | $4.15 | $20,731.50 |
DisclosureSEC source: 0001437749-23-006276 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,835 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-23-000135 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,500 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2023. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, Par Value $0.001 per share | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-23-000135 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 21:50 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-22-000612 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,500 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 21:50 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 15,000 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001161697-22-000612 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,500 Underlying: Common Stock · 15,000 shares Expires 2029-12-27 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 22:05 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-22-000578 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,500 Underlying: Common Stock · 1,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vested in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on December 6, 2022. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 22:05 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, Par Value $0.001 per share | 1,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-22-000578 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001161697-22-000413 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,834 Underlying: Common Stock · 20,000 shares Expires 2022-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on December 30, 2015 and previously vested in two annual installments. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 20,000 | $14.16 | $283,180.00 |
DisclosureSEC source: 0001161697-22-000413 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,207 F1 · shares: Dr. Tierney has advised the Company that the sale of shares was to pay the exercise cost of the shares and to raise funds for personal reasons and does not relate to any disagreements with the Company on any matter relating to the Company's operations, policies or practices. Dr. Tierney remains a Director of the Company. F2 · price: Shares were sold in various lots from $14.15 to $14.20 per share. The listed sales price represents A weighted average price for the shares sold. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 20,000 | $2.53 | $50,600.00 |
DisclosureSEC source: 0001161697-22-000413 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 21:20 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001437749-22-016303 · rdgdoc.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-27 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 28, 2022. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's seventh amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 00:30 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,000 | $4.39 | $8,780.00 |
DisclosureSEC source: 0001437749-22-013706 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,835 Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:30 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0001161697-22-000261 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,333 Underlying: Common Stock · 20,000 shares Expires 2022-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on December 30, 2015 and previously vested in two annual installments. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:30 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-22-000261 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,207 F1 · shares: Dr. Tierney has advised the Company that the sale of shares was to pay the exercise cost of the shares and to raise funds for personal reasons and does not relate to any disagreements with the Company on any matter relating to the Company's operations, policies or practices. Dr. Tierney remains a Director of the Company. F2 · price: 12,803 shares were sold at a price of $7.03 per share, 5,626 were sold at a price of $7.04 per share, and 1,571 were sold at a price of $7.05 per share. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:30 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 20,000 | $2.53 | $50,600.00 |
DisclosureSEC source: 0001161697-22-000261 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:05 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-22-000122 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,834 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person within sixty (60) days of vesting. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 21:50 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001161697-21-000622 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,834 Underlying: Common Stock · 20,000 shares Expires 2028-12-28 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 28, 2022, 1/3rd on December 28, 2023 and 1/3rd on December 28, 2024. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:13 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-21-000557 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,834 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 3, 2021. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 22:13 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, Par Value $0.001 per share | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-21-000557 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 30, 2021 Filed Nov 30, 2021 21:10 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,000 | $7.79 | $15,578.00 |
DisclosureSEC source: 0001437749-21-027552 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,835 Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:48 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 50,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001161697-21-000383 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,167 Underlying: Common Stock · 50,000 shares Expires 2021-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on August 28, 2014 and previously vested in two equal annual installments. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:48 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 50,000 | $6.08 | $303,895.00 |
DisclosureSEC source: 0001161697-21-000383 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,874 F1 · shares: Dr. Tierney has advised the Company that the sale of shares was to raise funds for personal reasons and does not relate to any disagreements with the Company on any matter relating to the Company's operations, policies or practices. Dr. Tierney remains a Director of the Company. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 20:48 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 50,000 | $3.12 | $156,000.00 |
DisclosureSEC source: 0001161697-21-000383 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 12:36 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-21-015183 · rdgdoc.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-16 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 17, 2021. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's sixth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 21:42 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001161697-21-000025 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,167 Underlying: Common Stock · 30,000 shares Expires 2027-12-30 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 30, 2021, 1/3rd on December 30, 2022 and 1/3rd on December 30, 2023. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-20-000590 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,167 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 22, 2020. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, Par Value $0.001 per share | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-20-000590 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 20:59 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,000 | $0.67 | $665.00 |
DisclosureSEC source: 0001437749-20-018283 · rdgdoc.xml · nonDerivative · entry 4 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,372 Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 20:59 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 4,500 | $0.66 | $2,970.00 |
DisclosureSEC source: 0001437749-20-018283 · rdgdoc.xml · nonDerivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,372 Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 20:59 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,000 | $0.65 | $1,290.00 |
DisclosureSEC source: 0001437749-20-018283 · rdgdoc.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,872 Read SEC document |
| August 18, 2020 Filed Aug 18, 2020 20:59 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 2,500 | $0.64 | $1,606.75 |
DisclosureSEC source: 0001437749-20-018283 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,872 Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 00:44 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001437749-20-013591 · rdgdoc.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-18 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the OTCQB Venture Market on the date of grant, June 19, 2020. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's fourth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:20 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-19-000516 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,500 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 22:20 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 33,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001161697-19-000516 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,500 Underlying: Common Stock · 33,500 shares Expires 2026-12-02 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:04 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 6,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-013393 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,372 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:54 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantOption to purchase common stock · Derivative | 360,000 | $0.84 Strike: $0.84 | $302,400.00 |
DisclosureSEC source: 0001424422-19-000007 · primary_doc.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Pres and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common stock · 360,000 shares Expires 2029-06-12 F1 · security: This option vests and becomes exercisable ratably over 36 months Read SEC document |
| May 10, 2019 Filed May 15, 2019 00:39 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantCommon Stock | 6,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-009881 · rdgdoc.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,944 F1 · shares: Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy. Read SEC document |
| April 24, 2019 Filed Apr 26, 2019 21:05 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001437749-19-008069 · rdgdoc.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-04-23 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, April 24, 2019. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's third amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:46 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 25,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-18-000621 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 25,000 shares Expires 2025-12-19 Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 21:46 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 25,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-18-000621 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 25,000 shares Expires 2025-12-19 Read SEC document |
| September 19, 2018 Filed Sep 20, 2018 20:01 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | PurchaseCommon Stock | 100,000 | $0.20 | $20,250.00 |
DisclosureSEC source: 0001104659-18-057805 · a4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500,000 Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 21:14 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantOption to purchase common stock · Derivative | 7,400,000 | $0.22 Strike: $0.22 | $1,628,000.00 |
DisclosureSEC source: 0001424422-18-000004 · primary_doc.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400,000 Underlying: Common stock · 7,400,000 shares Expires 2028-09-11 F1 · security: This option vests as to 25% of the shares subject to the option on the first anniversary date of the grant with an additional 1/36th of the remaining shares vesting monthly thereafter. Read SEC document |
| May 22, 2018 Filed May 24, 2018 20:06 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001437749-18-010654 · rdgdoc.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-21 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Market on the date of grant, May 22, 2018. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:58 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001161697-18-000038 · form4.xml · derivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 20,000 shares Expires 2025-01-02 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:58 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001161697-18-000038 · form4.xml · derivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 20,000 shares Expires 2025-01-02 Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:20 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 50,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001161697-17-000492 · form4.xml · derivative · entry 3 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 50,000 shares Expires 2017-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:20 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon stock, par value $0.001 per share | 7,860 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-17-000492 · form4.xml · nonDerivative · entry 2 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,541 F1 · price: Holder exercised 50,000 options at $0.47 per share via cashless exercise and was issued 42,140 shares based on the November 8, 2017 closing price of $2.99 per share. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:20 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 50,000 | $0.47 | $23,500.00 |
DisclosureSEC source: 0001161697-17-000492 · form4.xml · nonDerivative · entry 1 Tierney David S · CIK 0001292636 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Holder exercised 50,000 options at $0.47 per share via cashless exercise and was issued 42,140 shares based on the November 8, 2017 closing price of $2.99 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.